Insider · CIK 0002041689
Gregory L. Shiferman
officer
Files at SAGE (Sage Therapeutics, Inc.), VYGR (Voyager Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 6, 2026 | VYGR Voyager Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 8, 2026 |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | UTender of shares Common Stock | -7,215 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | DDisposition to issuer Common Stock | -23,735 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,000 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,000 | - | - | 0 | Jul 31, 2025 |
| Jun 24, 2025 | SAGE Sage Therapeutics, Inc. | FTax withholding Common Stock | -79 | $9.22 | $728 | 30,950 | Jun 26, 2025 |
| Apr 10, 2025 | SAGE Sage Therapeutics, Inc. | AGrant or award Common Stock | +525 | $0.00 | $0 | 31,205 | Apr 11, 2025 |
| Apr 10, 2025 | SAGE Sage Therapeutics, Inc. | FTax withholding Common Stock | -176 | $6.91 | $1,216 | 31,029 | Apr 11, 2025 |
| Dec 24, 2024 | SAGE Sage Therapeutics, Inc. | FTax withholding Common Stock | -79 | $5.48 | $433 | 19,888 | Dec 27, 2024 |
| Nov 1, 2024 | SAGE Sage Therapeutics, Inc. | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 19,967 | Nov 1, 2024 |
| Nov 1, 2024 | SAGE Sage Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Nov 1, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.